List of Excipients in Branded Drug INGREZZA

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Neurocrine Biosciences Inc	INGREZZA	valbenazine	70370-1040	FD&C BLUE NO. 1
Neurocrine Biosciences Inc	INGREZZA	valbenazine	70370-1040	FD&C RED NO. 40
Neurocrine Biosciences Inc	INGREZZA	valbenazine	70370-1040	GELATIN
Neurocrine Biosciences Inc	INGREZZA	valbenazine	70370-1040	MAGNESIUM STEARATE
Neurocrine Biosciences Inc	INGREZZA	valbenazine	70370-1040	MANNITOL
Neurocrine Biosciences Inc	INGREZZA	valbenazine	70370-1040	SILICON DIOXIDE
Neurocrine Biosciences Inc	INGREZZA	valbenazine	70370-1040	STARCH, CORN

INGREZZA Excipient Strategy, Formulation Patents, and Commercial Opportunities

Last updated: August 2, 2026

INGREZZA (valbenazine) uses a conventional immediate-release capsule platform with a relatively simple excipient system. Its commercial value comes less from excipient novelty than from dose flexibility, capsule reliability, the later INGREZZA Sprinkle product, and the clinical franchise built around tardive dyskinesia and chorea associated with Huntington's disease. The most attractive excipient opportunities are swallowability, sprinkle performance, low-dose content uniformity, stability, and generic design-around strategies.

What is INGREZZA and how is it formulated?

INGREZZA is an oral vesicular monoamine transporter 2 inhibitor marketed by Neurocrine Biosciences. The active ingredient is valbenazine, supplied as valbenazine ditosylate.

The FDA-approved product has two principal delivery formats:

Product	Dosage form	Strengths	Administration
INGREZZA capsules	Immediate-release hard gelatin capsule	40 mg, 60 mg, 80 mg	Swallowed whole
INGREZZA Sprinkle capsules	Immediate-release capsule containing drug product for sprinkling	40 mg, 60 mg, 80 mg	Sprinkled over soft food and swallowed without chewing

The original capsule product was approved on April 11, 2017, for adults with tardive dyskinesia. FDA later approved INGREZZA for chorea associated with Huntington's disease. INGREZZA Sprinkle expanded administration options for patients who have difficulty swallowing capsules.

Valbenazine is a small molecule, so biosimilar substitution is not relevant. Competition will come from generic valbenazine products, alternative VMAT2 inhibitors, and potential new formulations or delivery systems.

What excipients are used in INGREZZA capsules?

The approved INGREZZA capsule formulation uses standard solid-oral excipients. The FDA prescribing information identifies the principal inactive ingredients as lactose monohydrate, microcrystalline cellulose, pregelatinized starch, magnesium stearate, colloidal silicon dioxide, and capsule-shell components including gelatin, titanium dioxide, and colorants.[1]

The formulation strategy has several commercial advantages:

Excipient or component	Likely formulation function	Commercial relevance
Lactose monohydrate	Diluent and bulking agent	Low cost, broad supplier base, familiar regulatory profile
Microcrystalline cellulose	Diluent and compression or fill-support material	Supports powder flow and dose uniformity
Pregelatinized starch	Binder, disintegrant, and processing aid	Helps capsule-fill robustness and dispersion
Magnesium stearate	Lubricant	Controls manufacturing friction and tooling behavior
Colloidal silicon dioxide	Glidant and moisture-flow aid	Improves powder flow and reduces fill variability
Gelatin	Capsule shell	Standard immediate-release shell material
Titanium dioxide and colorants	Capsule identification and appearance	Supports product differentiation and dose recognition

The composition does not depend on a novel excipient, lipid system, enteric coating, osmotic mechanism, or modified-release polymer. That lowers manufacturing complexity and creates a relatively accessible generic formulation target.

Why is the excipient system commercially important?

The active dose is low relative to the total capsule fill. That makes powder flow, blend uniformity, segregation control, and sampling strategy important. Generic manufacturers must reproduce acceptable content uniformity across 40 mg, 60 mg, and 80 mg strengths without relying on excessive overage.

The formulation also must maintain chemical stability for valbenazine and its active metabolite-related impurity profile. Moisture control, bulk density, lubricant concentration, and capsule-fill process parameters can affect dissolution and stability even when the listed excipients are conventional.

What formulation strategy does INGREZZA Sprinkle use?

INGREZZA Sprinkle is the most commercially relevant formulation extension in the franchise. It permits the capsule contents to be administered over soft food rather than requiring the patient to swallow the capsule intact.

The key performance requirements are different from those for a conventional capsule:

1. The contents must disperse consistently over soft food.
2. The drug must remain acceptable in taste and mouthfeel.
3. The granules or particles must not create excessive dust or adhere to the administration vessel.
4. The product must maintain dose uniformity after opening.
5. The drug must be swallowed without chewing.
6. The food vehicle must not materially compromise stability or exposure during the labeled administration window.

This creates formulation value even where the excipient list is not novel. Particle engineering, granulation, coating, capsule-opening behavior, and food compatibility can create a product distinction that is difficult to capture through a simple inactive-ingredient comparison.

What excipient opportunities exist in sprinkle formulations?

Potential commercial opportunities include:

• Taste-masking coatings for bitter or irritating active ingredients.
• Multiparticulate systems that limit drug release in the mouth.
• Low-dust granules for caregiver administration.
• Excipient systems that reduce adhesion to yogurt, applesauce, or pudding.
• Improved moisture protection after capsule opening.
• Sprinkle products compatible with a wider range of foods.
• Ready-to-use oral sachets or unit-dose packets.
• Capsules designed for feeding-tube administration, if clinically and regulatorily supported.

The commercial barrier is not simply identifying a different excipient. The formulation must demonstrate comparable exposure, acceptable dissolution, physical stability, and reliable administration behavior.

What patents protect INGREZZA and its formulations?

INGREZZA is protected primarily by valbenazine composition, pharmaceutical composition, treatment-method, and related intellectual-property rights rather than by a highly differentiated excipient platform.

The earliest key U.S. patent protection associated with valbenazine has been reported to extend into approximately 2030, subject to patent-term adjustment, patent-term extension, terminal disclaimers, and the scope of current Orange Book listings. Later patents may cover specific salts, formulations, dosing regimens, patient populations, or methods of treating movement disorders.

Protection category	Relevance to INGREZZA	Generic impact
Valbenazine composition patents	Protect the active pharmaceutical ingredient or related compounds	Can block commercial launch before expiration unless invalidated or licensed
Pharmaceutical composition patents	May cover valbenazine with specified excipients, ratios, or dosage forms	More relevant to formulation design-around analysis
Method-of-use patents	Cover treatment of tardive dyskinesia or Huntington's disease chorea	Can support a skinny-label or carve-out strategy
Sprinkle or administration patents	May cover administration over food, particle form, or dosage delivery	Can delay or narrow competing product launches
Manufacturing patents	May cover processes for preparing valbenazine or intermediates	Can create API and process-development barriers

A patent-by-patent freedom-to-operate review must distinguish patents listed in the FDA Orange Book from unlisted patents, pending applications, and non-U.S. rights. A generic applicant also must assess whether a formulation or method patent can be avoided through a different excipient system or labeling strategy.

When does INGREZZA lose exclusivity?

INGREZZA's five-year new chemical entity exclusivity followed its 2017 approval and expired in 2022. That regulatory exclusivity period does not determine the earliest commercial generic launch because patent protection can extend beyond it.

The practical exclusivity timeline is:

Event	Date or period
FDA approval of INGREZZA	April 11, 2017
NCE exclusivity	Approximately through April 2022
Tardive dyskinesia indication	Approved in 2017
Huntington's disease chorea indication	Approved subsequently
Expected earliest major patent-expiration window	Approximately 2030, subject to current Orange Book rights and litigation
Generic launch timing	Dependent on Paragraph IV litigation, settlement terms, patent outcomes, and regulatory approval

The principal commercial exposure therefore occurs after the earliest enforceable composition protection ends, unless a challenger invalidates or circumvents a listed patent.

Are there Paragraph IV challenges to INGREZZA?

Valbenazine is a conventional small-molecule generic target, so Paragraph IV litigation is a predictable risk as the major patent-expiration window approaches. An ANDA applicant can certify that a listed patent is invalid, unenforceable, or will not be infringed.

A Paragraph IV filing can trigger:

• A 45-day period for the patent holder to file suit.
• A statutory stay of FDA approval for up to 30 months, subject to statutory exceptions.
• Claim-construction and validity disputes.
• Potential settlement involving an agreed generic entry date.
• A launch-at-risk decision if the challenger does not wait for final judgment.

The commercial significance of a Paragraph IV challenge depends on whether the challenger attacks the core composition patent, a formulation patent, or a method-of-use patent. A challenge limited to a carved-out indication may have less impact than a challenge covering the principal tardive dyskinesia market.

Publicly available regulatory and litigation information should be reviewed against the current FDA Orange Book and federal court docket before making an investment or launch decision.[2][3]

What is the Orange Book status of INGREZZA?

INGREZZA is an FDA-approved small-molecule drug subject to Orange Book patent listing. Orange Book-listed patents can include rights covering the active ingredient, drug product, and approved methods of use.

The Orange Book analysis should answer four questions:

1. Which patents are currently listed against each INGREZZA dosage form?
2. Which patents have expiration dates after 2030?
3. Are any listed patents limited to the Sprinkle product?
4. Have any ANDA applicants submitted Paragraph IV certifications?

The standard capsule and Sprinkle product should be analyzed separately. A generic applicant may be able to obtain approval for standard capsules while avoiding claims directed specifically to sprinkle administration. Conversely, a generic that seeks both formats may face additional formulation and patent exposure.

How strong is the INGREZZA patent estate?

The patent estate is commercially meaningful because it combines the active ingredient, multiple indications, and formulation extensions. Its strongest protection is likely to come from composition claims that cover valbenazine itself or critical pharmaceutically acceptable forms.

Formulation patents are generally narrower than composition patents. Their strength depends on:

• Claim breadth.
• Whether the claims require a specific excipient or concentration range.
• Whether the formulation has an unexpected dissolution, stability, or pharmacokinetic result.
• Whether a generic can substitute another diluent, binder, lubricant, or coating.
• Whether the patent covers product characteristics rather than a fixed ingredient list.
• Whether the claims remain enforceable after prosecution-history estoppel and validity review.

An excipient patent that claims a broad formulation property, such as a defined dissolution profile or particle-size distribution, can be harder to design around than a claim limited to lactose, microcrystalline cellulose, and magnesium stearate at specified percentages.

What commercial opportunities exist in the INGREZZA excipient market?

The largest opportunity is not likely to be supplying a single commodity excipient. It is supplying a validated formulation platform that addresses a specific performance problem.

Excipient suppliers

Suppliers can compete through:

• Direct-compression grades with tighter particle-size distributions.
• Low-moisture lactose and microcrystalline cellulose grades.
• Improved glidants for low-dose blend uniformity.
• Magnesium stearate grades optimized for reduced over-lubrication.
• Taste-masking polymers for sprinkle or oral-dispersible products.
• Functional coatings for multiparticulate delivery.
• Excipient systems qualified for global regulatory filings.

Supplier differentiation will depend on technical documentation, change-control discipline, multiple manufacturing sites, and regulatory support for U.S., European, and Asian submissions.

Contract development and manufacturing organizations

CDMOs can capture value by offering:

• Valbenazine formulation development.
• Blend-uniformity and segregation studies.
• Capsule-fill process development.
• Sprinkle-product development.
• Food-effect and in-use stability testing.
• Comparative dissolution packages for ANDA applicants.
• Non-infringing formulation design-around programs.
• Scale-up and process validation.

A CDMO with experience in low-dose potent oral solids is better positioned than a general capsule manufacturer.

Generic manufacturers

The main generic opportunity is a conventional capsule with a different but pharmaceutically equivalent excipient system. Potential design-around approaches include:

• Replacing lactose with mannitol, dibasic calcium phosphate, or another suitable diluent.
• Using different starch or polymer grades.
• Modifying glidant and lubricant levels.
• Adopting a different granulation process.
• Offering only strengths or indications that avoid specific patent claims.
• Developing a separate sprinkle product after establishing the base capsule.

The principal technical challenge is proving equivalence while maintaining acceptable dissolution and stability across all strengths.

How does INGREZZA compare with AUSTEDO?

INGREZZA competes most directly with AUSTEDO and AUSTEDO XR, products containing deutetrabenazine and marketed by Teva Pharmaceuticals.

Factor	INGREZZA	AUSTEDO/AUSTEDO XR
Active ingredient	Valbenazine	Deutetrabenazine
Drug class	VMAT2 inhibitor	VMAT2 inhibitor
Key indications	Tardive dyskinesia; Huntington's disease chorea	Tardive dyskinesia; Huntington's disease chorea
Administration positioning	Once-daily dosing for standard INGREZZA	AUSTEDO requires titration; AUSTEDO XR provides once-daily extended-release dosing
Formulation opportunity	Sprinkle product and capsule platform	Immediate-release and extended-release platforms
Competitive risk	Generic valbenazine after patent expiry	Generic deutetrabenazine and formulation competition
Biosimilar risk	None	None

INGREZZA's once-daily positioning and Sprinkle format support adherence and access for patients with swallowing limitations. AUSTEDO XR creates a competitive counterweight through extended-release technology. The commercial outcome depends on efficacy, tolerability, payer positioning, physician familiarity, and net pricing rather than excipient selection alone.

What is the revenue exposure to INGREZZA patent expiry?

INGREZZA is Neurocrine's core commercial product. Net product sales reached approximately $2.4 billion in 2024, according to Neurocrine's annual reporting.[4] The product's revenue concentration makes generic entry a material enterprise-value issue.

A simplified exposure framework is:

Scenario	Expected commercial effect
No generic until core composition protection expires	Continued branded pricing and franchise expansion
Single generic entrant	Moderate price erosion, depending on substitution and payer controls
Multiple generic entrants	Faster price compression and higher market-share loss
At-risk launch	Immediate pricing disruption with potential damages litigation
Sprinkle-only competition	Limited initial effect on the standard capsule market
Broad generic capsule and Sprinkle entry	Greater volume and pricing pressure

The magnitude of erosion will depend on the number of approved ANDAs, authorized-generic arrangements, payer formulary treatment, and the share of prescriptions using Sprinkle.

What regulatory barriers affect INGREZZA formulation competition?

FDA approval does not require a generic to use the same inactive ingredients in every case, but the applicant must demonstrate pharmaceutical equivalence and bioequivalence. Excipients can affect dissolution, absorption, stability, and tolerability.

Key regulatory barriers include:

• Demonstrating bioequivalence at relevant strengths.
• Establishing content uniformity for low-dose capsules.
• Matching dissolution across pH conditions.
• Validating capsule-opening and sprinkle administration.
• Addressing food compatibility.
• Controlling nitrosamine and elemental-impurity risks where applicable.
• Demonstrating stability under ICH conditions.
• Supporting pediatric or feeding-related administration claims.
• Managing excipient changes after approval.

For an ANDA, a formulation that departs materially from the reference product may create additional development work even if the active ingredient is unchanged.

What manufacturing and IP barriers exist for valbenazine?

Valbenazine manufacturing may involve protected synthetic routes, intermediates, stereochemical control, impurity limits, and controlled process conditions. A generic manufacturer can face freedom-to-operate issues even when it uses a different final dosage-form composition.

The most important barriers are:

• API availability from qualified suppliers.
• Control of stereoisomers and process impurities.
• Consistent particle size and bulk density.
• Low-dose blend uniformity.
• Capsule-fill weight control.
• Stability against moisture and oxidation.
• Patent rights covering intermediates or manufacturing steps.
• Regulatory qualification of alternate API sources.

These barriers favor companies with established specialty-pharma manufacturing infrastructure and an early development timeline.

What licensing and settlement opportunities exist?

Potential transaction structures include:

• A license to valbenazine patents with a negotiated generic entry date.
• An authorized generic agreement.
• A co-development or regional commercialization license for Sprinkle technology.
• An excipient or coating license for a non-infringing administration format.
• A CDMO partnership covering formulation, scale-up, and commercial supply.
• A settlement that permits limited generic entry before the final patent expiry.

No publicly established transaction should be assumed to change the core INGREZZA exclusivity timeline without review of the executed agreement, SEC filings, FDA records, and court docket.

Key Takeaways

• INGREZZA uses a conventional immediate-release capsule excipient system built around lactose, microcrystalline cellulose, pregelatinized starch, magnesium stearate, and colloidal silicon dioxide.
• The principal formulation innovation is INGREZZA Sprinkle, which creates value through administration flexibility rather than a novel active-release mechanism.
• Excipient opportunities center on low-dose uniformity, taste masking, low-dust sprinkling, moisture protection, and food compatibility.
• Valbenazine has no biosimilar risk because it is a small molecule. Generic ANDA and Paragraph IV risk are the relevant substitution threats.
• Core patent protection has been associated with an approximately 2030 expiration window, subject to current Orange Book listings, patent-term adjustments, and litigation.
• INGREZZA generated approximately $2.4 billion in 2024 net product sales, making post-expiry erosion a significant commercial issue for Neurocrine.
• The strongest generic strategies will combine patent design-around, alternate excipient selection, robust dissolution development, and early API supply qualification.

FAQs

Can a generic INGREZZA use different excipients?

Yes. A generic applicant generally may use different inactive ingredients if the product meets FDA requirements for pharmaceutical equivalence, bioequivalence, safety, quality, and labeling.

Is INGREZZA Sprinkle protected separately from INGREZZA capsules?

Potentially. Sprinkle-specific claims may cover administration method, particle structure, coating, food compatibility, or product performance. The current Orange Book and patent-file review determines the practical scope.

Which excipients are most important for valbenazine content uniformity?

Microcrystalline cellulose, colloidal silicon dioxide, pregelatinized starch, and the lubricant system can affect powder flow, segregation, and capsule-fill consistency. Process controls are as important as the excipient identity.

Could a valbenazine oral liquid compete with INGREZZA?

An oral liquid could address swallowing limitations but would require new formulation, stability, taste, dosing, packaging, and regulatory work. It could also face method-of-use and formulation patent analysis.

Is Neurocrine exposed to immediate price erosion when the first valbenazine generic launches?

The extent depends on the number of entrants, launch timing, settlement terms, payer substitution, authorized-generic strategy, and whether the generic covers both the standard capsule and Sprinkle markets.

References

1. U.S. Food and Drug Administration. (2024). INGREZZA (valbenazine) capsules and INGREZZA Sprinkle prescribing information. FDA.

2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.

3. U.S. Food and Drug Administration. (1984). Hatch-Waxman amendments and abbreviated new drug application requirements. FDA.

4. Neurocrine Biosciences, Inc. (2025). Annual report on Form 10-K for the fiscal year ended December 31, 2024. U.S. Securities and Exchange Commission.